TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CYSTOGRAFIN DILUTE

DIATRIZOATE MEGLUMINE
Approved 1955-08-02
4
Indications
--
Phase 3 Trials
70
Years on Market

Details

Status
Prescription
First Approved
1955-08-02
Routes
URETHRAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: DIATRIZOATE MEGLUMINE

CYSTOGRAFIN DILUTE Approval History

Loading approval history...

What CYSTOGRAFIN DILUTE Treats

1 indications

CYSTOGRAFIN DILUTE is approved for 1 conditions since its original approval in 1955. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cystourethrography
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CYSTOGRAFIN DILUTE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

INDICATION Cystografin Dilute is indicated for retrograde cystourethrography.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.